Clinical trial
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
NCT00020930 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00020930 |
|---|---|
| Title | Cetuximab in Treating Patients With Stage IV Colorectal Cancer |
| Official title | Phase II Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Patients With Irinotecan-Refractory, Stage IV Colorectal Carcinoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological |
| Interventions | cetuximab |
| Start date | Mar 1, 2001 |
| Primary completion | Aug 1, 2002 |
| First posted | Mar 17, 2004 |
| Last update posted | Dec 4, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: